Global Pharma Management

Several studies investigating the role of miRNAs showed evidence for their influence in cell development processes. Recently, promising biomarkers for the future diagnosis and differentiation of lung cancer and multiple sclerosis have been published in BMC Cancer and PLoS ONE. The results demonstrated that miRNA biomarkers reliably distinguish between affected and healthy individuals by analysing whole blood samples. Each miRNA is part of a meaningful pattern giving information about individual regulatory processes. Therefore each miRNA of the Geniom Biochip, from either miRBase 14 or the SOLiD sequencing-studies, will be of high scientific impact and can be a potential biomarker candidate or therapeutically relevant molecules.

Peer Staehler, febit's CSO, said: "After the recent publication of promising results in biomarker discovery febit now enhanced its pipeline with novel, well validated content. febit plans to  develop miRNA and other disease-related biomarkers which will help to detect diseases at early stages, diagnose the disease progression and monitor the response to treatment. In our studies we used whole blood, which is a well established sample source in the diagnostic practice."

febit's highly flexible microarray production technology keeps pace with the advances in genomic research and the speed of discovery in this exciting industry. febit's Geniom RT Analyzer platform enables febit's customers to conduct large cohort studies due to the very high degree of automation and sophisticated bioinformatics is then able to interpret data to reveal significant regulatory patterns.